To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Reduced Blood Loss and Pain & Improved ROM with TXA Plus Post-Op Knee and Hip Flexion After TKA

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
February 2021

Reduced Blood Loss and Pain & Improved ROM with TXA Plus Post-Op Knee and Hip Flexion After TKA

Vol: 10| Issue: 2| Number:9| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Reduction of Blood Loss by Intra-articular Injection of Tranexamic Acid Combined with Knee and Hip Flexion at 45° During Primary Total Knee Arthroplasty: A Randomized Controlled Trial

Orthop Surg. 2020 Dec;12(6):1835-1842

Contributing Authors:
L Yang L Zhao J-S Tan K-P Huo D-Z Cai J-Q Yang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Ninety-six patients with moderate/severe knee osteoarthritis (OA) were randomized to receive an intra-articular injection of tranexamic acid (TXA) plus knee and hip flexion for 4 hours after total knee arthroplasty (TKA; n=48) or control (saline injection with limb fully extended post-operation; n=48). The primary outcome of interest was the change in hemoglobin levels measured at 6 hours and 1, ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue